Finally, focusing on the EGFR-mutated NSCLC BM system, this study observed that BM resistance after TKI, which was not accounted for in the previous BM scoring systems, could identify the patients with the worst outcomes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.